Stephens Consulting’s Arcellx ACLX Stock Holding History

Stephens Consulting’s Portfolio ACLX Stock Details ACLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-15	Closed	-$984	–	1196
2025 Q1	$984	Buy	+15	New	+$1.02K	﹤0.01%	651

Other funds holding ACLX

Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

SOCM

SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return

Stephens Consulting's ACLX Position: Q2 2025 in Review

Stephens Consulting sold out of Arcellx (ACLX) in Q2 2025, closing a stake of 15 shares — an estimated $984 sold.

Stephens Consulting first reported a position in ACLX in Q1 2025 and held it in 1 quarter. The position peaked at $984 in Q1 2025. 202 funds tracked by Wall St. Rank hold ACLX as of Q2 2025.

Stephens Consulting reported no remaining Arcellx position as of Q2 2025 after selling out during the quarter.
Stephens Consulting sold 15 Arcellx shares in Q2 2025, an estimated $984.
Stephens Consulting first reported a position in Arcellx in Q1 2025 and held it in 1 quarter.
Stephens Consulting's Arcellx position peaked at $984 in Q1 2025.
202 funds tracked by Wall St. Rank held Arcellx as of Q2 2025.

Based on Stephens Consulting's 13F filing for Q2 2025, filed 25 Jul 2025.